पहचान

Eletriptan Hydrobromide

सूचीबद्ध नहीं · C22H27BrN2O2S

01पहचान

Lazychem IDLC-103527
CAS RNसूचीबद्ध नहीं
PubChem CID656631
Molecular formulaC22H27BrN2O2S
Molecular weight463.4 g/mol
IUPAC name5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole;hydrobromide
InChIKeyUTINOWOSWSPFLJ-FSRHSHDFSA-N

02संरचना और त्रिविम रसायन

2D structurePubChem CID 656631
Two-dimensional chemical structure of Eletriptan Hydrobromide
Two-dimensional structure for the PubChem identity linked to this record. Confirm the identifiers before analytical use.

The parsed structure contains 4 rings, includes aromatic atoms, includes aliphatic carbon, has 1 defined stereocentre, contains at least one halogen atom. These statements are calculated from the published structure string.

Defined stereocentres1
Ring count4
Secondary amines0
Tertiary amines1
SMILESCN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4.Br
InChIसूचीबद्ध नहीं

03Stereochemistry

The published structure contains 1 defined and 0 unassigned tetrahedral stereocentre. The exact wedge and dash depiction is shown above.

Defined centres1Structure assigned
Unassigned centres0Structure unspecified
Assignment statusFully assignedExact published identity
Tetrahedral upper bound≤ 2Before symmetry reduction

Published same-connectivity configurations

1 record

These records have the same connectivity, molecular formula and protonation layer, but a different complete InChIKey stereochemical layer. Only separately structure-linked records are shown.

No additional structure-linked configuration with the same connectivity is currently present in the LazyChem dataset.

Scope: The mathematical 2^n value is only an upper bound. Symmetry and other stereogenic elements can change the number of distinct stereoisomers. A hypothetical configuration is not published as a compound record without a verified structure identity.

04भारत में स्थिति

Exact-compound status is evaluated only against the published name and CAS number. Confirm the current official instrument before a regulatory decision.

05नाम और संबंध

API और मूल औषधि

सूचीबद्ध नहीं

नाम और संबंध

    अशुद्धियाँ और संबंधित यौगिक

      06स्रोत